Investors of Reckitt Benckiser Group PLC Urged to Lead Securities Fraud Lawsuit

The Rosen Law Firm, renowned for its advocacy of investor rights, is calling attention to a significant opportunity for those who acquired American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC (OTC RBGLY) between January 13, 2021, and July 28, 2024. This alert pertains to a class action lawsuit related to allegations of securities fraud concerning Reckitt's products and misleading statements about their safety, particularly involving the Enfamil formula.

Important Date for Investors

As potential plaintiffs, investors must be aware of the crucial deadline to assume a leading role in this case. If you procured Reckitt ADSs during the specified period, you should know about the impending August 4, 2025, deadline for filing motions to serve as lead plaintiff in the class action. This is a vital date for those affected, and acting swiftly could be imperative for your potential compensation.

Compensation Without Out-of-Pocket Fees

One of the more encouraging aspects of this legal action is that eligible investors can pursue compensation without the burden of upfront fees or costs. The Rosen Law Firm operates under a contingency fee arrangement, meaning that the firm only charges if compensation is secured. This model allows potential plaintiffs to feel secure in joining the lawsuit without financial risk.

Next Steps for Interested Investors

Interested investors are encouraged to take immediate action to ensure their participation in the class action lawsuit. For those looking to join this essential legal battle, visit rosenlegal.com or contact Phillip Kim, Esq. toll-free at 866-767-3653. Email inquiries can be sent to [email protected] to obtain additional information regarding the class action.

Background of the Case

The lawsuit contends that during the class period, Reckitt Benckiser failed to effectively warn investors about serious risks linked to its infant formula, Enfamil. Reports indicate that preterm infants consuming this product are at heightened risk for developing necrotizing enterocolitis (NEC). Such a serious health risk was reportedly kept from the public eye, misleading investors about Reckitt's product safety and overall business well-being.

The following issues are at the heart of the allegations:
1. Failure to inform stakeholders about the risks of NEC associated with Enfamil formula.
2. Lack of transparency regarding the product’s effects on sales and impending legal challenges.
3. Misleading statements about Reckitt's business prospects that were not supported by factual evidence.

As the information surrounding these claims emerges, investors may find themselves facing significant damages due to the misleading nature of the company's statements.

Importance of Choosing Qualified Counsel

The Rosen Law Firm underscores the necessity of selecting capable and experienced legal counsel. Not all firms that signal interest in representing investors have the depth of experience needed to handle securities class actions effectively. Rosen Law Firm boasts a proven track record, having secured substantial settlements in previous cases, including the largest-ever securities class action settlement against a Chinese company at the time. Investors are advised to conduct due diligence when allotting counsel for such critical legal matters.

Continuous Updates

The Rosen Law Firm encourages all potential class members to stay updated on the latest information regarding the lawsuit. You can follow their updates and announcements on their social media platforms, including LinkedIn, Twitter, and Facebook.

Conclusion

For those who purchased Reckitt Benckiser Group PLC ADSs within the defined temporal limits, this lawsuit presents a significant opportunity for recourse. Moving quickly to secure a role in this class action could offer avenues for not just justice but also restitution for losses incurred due to alleged corporate misrepresentation and negligence. If you believe you have a claim, do not hesitate to reach out to the Rosen Law Firm today.